A third patient receiving Sarepta's gene therapy for limb-girdle muscular dystrophy died from acute liver failure, intensifying safety concerns around the company’s gene therapy portfolio. This fatality followed two previous deaths involving the Duchenne muscular dystrophy gene therapy Elevidys. Sarepta acknowledges the incidents and is collaborating with the FDA amid increased scrutiny. The company is engaging in efforts to mitigate risks, including a proposed black box warning on Elevidys and modifications to immunosuppression protocols.